by Leigh Mack
The problem we solve: Imagine having to receive shots in your body every 2 to 3 months for the rest of your life for a medical condition? Onabotulinumtoxin A has many FDA approved indications in which patients receive shots of Onabotulinumtoxin A every 2 to 3 months indefinitely for conditions such as: chronic migraines, overactive bladder (bladder dysfunction), upper and lower limb spasticity, cervical dystonia, and primary axillary hyperhidrosis.
About our solution: By changing the diluent from saline to an aqueous based solution with an Ag4O4, crystalline structured silver nanoparticle; the discovery was made that you could extend the efficacy to over 200%.Progress to date:
Currently, a Phase 1 trial has been completed with 17 healthy participants from 2013 to 2014 resulting in an average efficacy period of 9 months. As of 2016, No adverse events were reported and no adverse drug reactions were reported. This Phase 1 trial of Onabotulinumtoxin A and Ag4O4 combination has been completed in British Colombia, Canada.
Creator: Leigh Mack
Education: University of Oxford and USAT Montserrat
Bio: Dr. Leigh J. Mack is an alumni of Indiana State University He is also a graduate of USAT Montserrat; holding both a MD and PhD degrees. Dr. Mack has post graduate training in Nanotechnology (nanomedicine) from University of Oxford. He trained at John Radcliffe Hospital (University of Oxford/NHS) in Trauma Plastics. Dr. Mack is a Certified Principal Investigator (CPI - ACRP); and a Fellow of the Academy of Physicians in Clinical Research. He is currently pursuing a Fellowship with ACC.
Hospital Affiliation: Mack Biotech, Corp, Inaline Corp, Emergency EMCG, Inc.
Advanced Degree(s): MD, PhD, FAPCR, CPI
Biography: Dr. Willoughby graduated with a Doctorate of Dental Medicine (DMD) from the University of Manitoba in 1988 with awards in crown and bridge work and operative dentistry. Dr. Willoughby has a very diverse clinical background and many clinical interests. Dr. Willoughby also has a special interest in helping treat patients who suffer from TMJ and Headache pain as well as restoring badly broken down bites using unique precision attachment partial dentures and over-dentures.
Advanced Degree(s): DMD
Biography: Keith is a graduate Brigham Young University and is the Chief Executive Officer of American Biotech Labs, LLC. (ABL) and a owner of Clifton Mining Company. ABL is the manufacturer of the nanoparticle that has been employed in this new discovery.
Advanced Degree(s): ND
Imagine having to receive shots every 2 to 3 months for the rest of your life for a medical condition? Onabotulinumtoxin A has many FDA approved indications, in which patients receive shots of Onabotulinumtoxin A, every 2 to 3 months indefinitely for a lifetime for conditions such as: chronic migraines, overactive bladder (bladder dysfunction), upper and lower limb spasticity, cervical dystonia, and primary axillary hyperhidrosis. We can't fix the conditions, but we possibly extend those shots to just every 8 to 9 months.
This a potential game changer for providers in being able to offer a btter qaulity of life to patients by being able to treat more eefctively at greater intervals.
No comments found .
No updates found .
Help us find best new ideas to fund by telling us what you think. Your feedback goes straight to the team behind this project in private, so tell them what you really think.